In 2023 an RCT containing infertile women with PCOS undergoing ART cycles and at risk of OHSS, the effectiveness of combined treatment with letrozole, mifepristone, and GnRH antagonist was compared to a group using only mifepristone for OHSS prevention. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.